The POU domain gene, XlPOU 2, acts as a transcriptional activator during mid-gastrulation in Xenopus. Overexpression or misexpression of VP16-POU-GR, a fusion protein consisting of the strong activator domain of VP16 and the POU domain of XlPOU 2, results in ectopic expression of the neural-speci®c genes, nrp-1, en-2, and b-tubulin. In contrast, overexpressing a dominant-inhibitory form of XlPOU 2 inhibits the chordin-induced neuralization of uncommitted ectoderm, and results in a loss of nrp-1 and en-2 expression in embryos. Furthermore, in uncommitted ectoderm, XlPOU 2 regulates the developmental neural program that includes a number of pre-pattern genes and at least one proneural gene, X-ngnr-1, thus playing a key role during neural determination. q
Introduction
In Xenopus, dorsalizing factors produced by Spemann's organizer during gastrulation can neuralize the ectoderm in a process known as neural induction. By antagonizing the action of ligands such as BMP-4, the dorsalizing factors, noggin (Smith and Harland, 1992; Zimmerman et al., 1996) , chordin (Sasai et al., 1994; Piccolo et al., 1996) , follistatin (Hemmati-Brivanlou et al., 1994) , Xnr3 (Smith et al., 1995; Hansen et al., 1997) and cerberus (Bouwmeester et al., 1996; Hsu et al., 1998) block the ventralization of ectoderm by preventing signaling events downstream from the BMP receptor. The end result of this blockade is formation of the nervous system (Piccolo et al., 1996; Zimmerman et al., 1996; Fainsod et al., 1997 ; for recent reviews, see Harland, 1997; Sasai and De Robertis, 1997; Wilson and Hemmati-Brivanlou, 1997; Sasai, 1998) .
After neural induction, during gastrulation to early neural plate formation, neuroectoderm cells are speci®ed (committed to a neural cell fate, a reversible event), and then determined (committed to a neural cell fate, an irreversible event) Sharpe and Gurdon, 1990; Slack, 1989) . Neural speci®cation and determination are regulated by a number of transcription factors. One of these transcriptional regulators, the POU domain gene, XlPOU 2, is thought to play an important role in mediating neural determination. XlPOU 2 is downstream from neural inductive signaling events, and is activated by the neural inducer, noggin, during gastrulation (Witta et al., 1995) . Moreover, XlPOU 2 is expressed in the presumptive neuroectoderm during gastrulation (Witta et al., 1995) and is capable of directly inducing the expression of the neural speci®c gene NCAM (Kintner and Melton, 1987) and the neuronal marker, b -tubulin (Good et al., 1989) , in uncommitted ectoderm.
Since XlPOU 2's initial characterization as a downstream determinant in neural induction (Witta et al., 1995) , a host of other genes encoding transcriptional regulators have been identi®ed that also mediate neural induction. The earliest expressed genes that respond to neural induction are the pre-pattern genes. These include members of the Zic gene family (Zic 1 (Kuo et al., 1998) , Zic r1 (Mizuseki et al., 1998) , Zic 2 (Brewster et al., 1998) , and Zic 3 (Nakata et al., 1997) ), members of the iro family (ara, caup), Xiro 1, 2 and 3 (Bellefroid et al., 1998; Go Âmez-Skarmeta et al., 1998) , geminin (Kroll et al., 1998) and Sox 2 (Mizuseki et al., 1998) . Some of these genes are expressed in discrete regions of the dorsal ectoderm by the early gastrula stage, and at least one of the pre-pattern genes, Zic 1 is not induced by neural inducers per se, but has been shown to in¯uence neural competence (Kuo et al., 1998) . Furthermore, during mid-gastrulation, proneural genes such as Xash-3 (Zimmerman et al., 1993; Ferreiro et al., 1994; Turner and Weintraub, 1994) , ATH-3 (Takebayashi et al., 1997) , X-ngnr-1 (Ma et al., 1996) and neuroD (Lee et al., 1995) regulate neural determination and differentiation. These genes are members of the basic helix-loop-helix family (bHLH) and are vertebrate homologs of the Drosophila achaete-scute complex and atonal, which together control neuronal differentiation (Chien et al., 1996 ; for a review, see Anderson and Jan, 1997) . Although many vertebrate homologs of Fig. 1 . Constructs of the XlPOU 2 activator and repressor. (A) A full length XlPOU 2 cDNA, containing the POU domain (encoding residues 1±361), was fused to the ligand-binding domain of glucocorticoid receptor (GR; encoding residues 512±777). (B) The POU domain of XlPOU 2 (encoding residues 192-361), was fused to a VP16 activator (encoding residues 410±490) and GR (VP16-POU-GR). (C) The mutated POU domain of XlPOU2 (encoding residues 192-318), was fused to a VP16 activator and GR (VP16-POU-DEL-GR). (D) The POU domain of XlPOU 2 (encoding residues 192±361) was fused to an engrailed repressor (encoding residues 1±298) and GR (ENG-POU-GR). (E) The mutated POU domain of XlPOU2 (encoding residues 192±318), was fused to an engrailed repressor and GR (ENG-POU-DEL-GR). The corresponding base pairs are shown at the top of the schematic. , and embryos were subsequently treated with dex at stage 11 or 14 and collected at stage 20±22. The embryos treated with dex at stage 11 show increased nrp-1 expression (A; black arrowhead in the inset shows the expanded region) and ectopic expression of b-tubulin (C) only in the injected sides (turquoise). However, embryos that were treated with dex at stage14 display a normal pattern of expression for both nrp-1 and b-tubulin (B and D, respectively) . The non-dex-treated embryos also show a normal pattern of expression for both genes (A H , B H , C H , and D H ). White arrows depict the enlarged region shown in the insets. Abbreviations: nt, notochord.
proneural genes have been isolated and studied (for a review see Lee, 1997) , the relationship between these genes is not well-understood. In this report, we further investigate the role of XlPOU 2 during neural determination. We address several important questions: (1) Does XlPOU 2 act as a transcriptional activator or repressor during neural determination? (2) Is XlPOU 2's activity required for neural determination? (3) When is the critical period of XlPOU 2's action during neural determination? (4) Do the pre-pattern genes induce XlPOU 2 and vice versa? (5) What kind of neural tissue is induced or speci®ed by XlPOU 2? We provide evidence that XlPOU 2 works as a transcriptional activator during gastrulation, and is capable of inducing a number of pre-pattern genes, and at least one proneural gene, X-ngnr-1. Furthermore, we demonstrate that XlPOU 2's activity is essential in the developmental neural pathway. As more transcriptional regulators of this developmental pathway have been identi®ed in recent years, it has been important to understand XlPOU 2's relationship to these genes. We provide a working model describing XlPOU 2's role in neural determination.
Results

XlPOU 2 acts as an activator of transcription during neural determination
To investigate whether XlPOU 2 acts as a repressor or an activator of transcription, the presumptive transactivation domain, deduced from studies of XlPOU 2's mammalian homolog, Brn-4 (Mathis et al., 1992) , was replaced with either the strong transcriptional activation domain of VP16 (VP16-POU) or the strong transcriptional repressor domain of engrailed (ENG-POU). The ligand binding domain of the human glucocorticoid receptor (GR) (Hollenberg et al., 1985) was fused to these constructs (Fig. 1B,D ) and the addition of dexamethasone (dex) to the culture media was used to control the temporal expression of the proteins made from these constructs. Microinjection of 20± 100 pg of VP16-POU-GR mRNA at the 8±16 cell stage into a dorsal animal blastomere that gives rise to the entire central nervous system (CNS) led to an expansion of the expression domain of the pan-neural marker, nrp-1 (n 30, 60%) (compare Fig. 2A to 2A H ), and the midbrain-hindbrain boundary (MHB) marker, en-2 (n 18, 66%) (compare Fig.  5E to 5F). Moreover, when 100±200 pg of VP16-POU-GR mRNA was injected into a ventral animal blastomere at the 8±16 cell stage, the ectopic expression of b -tubulin was detected only on the injected side of dex-treated embryos (n 35, 88%) (compare Fig. 2C to 2C H ). Induction of btubulin was also observed when 40 or 200 pg of XlPOU 2-GR mRNA (Fig. 1A ) was similarly injected (data not shown). These results are consistent with previous observations in which the misexpression of full length XlPOU 2 mRNA into a ventral animal blastomere at the 32-cell stage induced ectopic b-tubulin expression (Witta et al., 1995) . Thus, these studies collectively suggest that XlPOU 2 acts as an activator of transcription during neural determination.
Expression of a dominant-inhibiting form of XlPOU 2 blocks neural induction and leads to a loss of neural-speci®c gene expression
A dominant-inhibiting construct of XlPOU 2, ENG-POU-GR ( Fig. 1D) , was utilized to assess the importance of XlPOU 2 as a transcriptional activator of neural determination. In contrast to the activator, microinjection of 60±300 pg of ENG-POU-GR mRNA into a speci®c dorsal animal blastomere at the 8±16 cell stage led to a partial or in rare cases, a complete loss of nrp-1 (n 41, 61% show a loss in expression) (compare Fig. 3A ,B) and en-2 expression (n 55, 35% show a loss of expression) (compare Fig.  5G and 5H) in dex-treated embryos. Interestingly, in experiments examining the expression of both nrp-1 and epidermal keratin by in situ hybridization, cells in the neural tube that showed a loss of nrp-1 expression did not express epidermal keratin (data not shown). Thus, when the neural cell fate is blocked, these cells do not by default convert to an epidermal cell fate. The speci®city of ENG-POU-GR in binding to its target gene was examined by microinjecting a mutated form of the POU domain, ENG-POU-DEL-GR (300 pg mRNA) into a speci®c dorsal animal blastomere at the 8±16 cell stage. Embryos that were injected with this construct showed no loss of neural tissue (data not shown). Moreover, co-injection of VP16-POU-GR (100 pg) and ENG-POU-GR (300 pg) did not result in an expansion of the neural plate (data not shown), suggesting that ENG-POU-GR could completely negate the effects of VP16-POU-GR construct.
If XlPOU 2 is essential for neural induction, then ENG-POU-GR should inhibit the process of neural induction. We tested this possibility by neuralizing animal caps with the neural inducer, chordin (50 pg). And the ability of ENG-POU-GR (200 pg) to block chordin's action was assessed by examining the induction of two neural-speci®c markers, Zic-3 and nrp-1. ENG-POU-GR reduced Zic 3 expression by 57% and nrp-1 expression by 67% in dextreated animal caps as assayed by Northern blot analysis (Fig. 4) . Thus, the dominant-inhibiting construct of XlPOU 2, ENG-POU-GR, inhibited neuralization by chordin. 
Mid-to late gastrulation is the critical time frame for XlPOU 2's action as a neural determinant
In order to determine the time frame of XlPOU 2's action as a neural determinant, the overexpression and misexpression of VP16-POU-GR was activated by the addition of dex to the culture medium at stage 11 (mid-gastrulation) or by delaying its addition until just after gastrulation (approximately 3 h later, stage 13±14). Because XlPOU 2 is expressed in the neuroectoderm during gastrulation (Witta et al., 1995) , it was reasoned that XlPOU 2's action as a neural determinant should take place during mid-to late gastrulation. Activation of the VP16-POU-GR by dex at stage 11 led to neuralization of the ectoderm, and expansion of the neural plate, changes re¯ected in both the expansion and ectopic expression of nrp-1 and b -tubulin ( Fig. 2A and  2C , respectively). In controls, the injected embryos that were not treated with dex showed no ectopic neuralization or expansion ( Fig. 2A H and 2C H , respectively). Interestingly, the window of XlPOU 2's action as a neural determinant ended at the beginning of neural plate formation (stage 13± 14), coinciding with the end of neural determination. When dex is added to embryos after this stage, no neuralization (ectopic neurons or expansion of the neural plate) was observed (compare Fig. 2B ,B H and 2D,D H ). To eliminate the possibility that the injected mRNA was degraded, and became ineffective by stage 13±14, extracted RNA prepared from the injected embryos was assessed by gel blot analysis. RNA of the expected size was readily detected even in the older embryos (data not shown).
2.4. Zic 3 and Zic r1, but not X-ngnr-1, induce XlPOU 2 in animal cap ectoderm
The activation of pre-pattern genes occurs at the beginning of gastrulation, and thus they are likely candidates to work upstream from XlPOU 2, which is not expressed in the neuroectoderm until mid-gastrulation. The induction of XlPOU 2 by both Zic 3 and by Zic r1 was investigated after the overexpression of these genes in animal cap ectoderm. Both genes were capable of neuralizing animal cap ectoderm, as evidenced by the activation of nrp-1 (Fig.  6A,B ). They were also capable of weakly inducing XlPOU 2 (Fig. 6A,B) . These results extend and corroborate the previous ®ndings of Nakata and colleagues (1997) . Furthermore, the activation of several neural-speci®c genes, including XlPOU 2, was examined after the overexpression of X-ngnr-1 in an animal cap assay. The data indicate that X-ngnr-1 is not capable of inducing XlPOU 2 (Fig. 6C) .
XlPOU 2 activates both pre-pattern and proneural genes
The activation of several pre-pattern and neuronal determination genes by VP16-POU-GR was investigated utilizing an animal cap assay, combined with a RT-PCR analysis. VP16-POU-GR induced Zic r1, Zic 3, and X-ngnr-1 (Fig.  7A) . As expected the mesoderm-speci®c gene, Xbra (Smith, et al., 1991) was not induced, and the ubiquitously expressed gene, Ef1a (Krieg et al., 1989) was not altered (Fig. 7A) . A similar pattern of induction was observed with microinjection of the XlPOU 2-GR construct (Fig. 7B) . Moreover, no neural marker genes were induced when the control, VP16-POU-DEL-GR, was injected (data not shown), suggesting that the induction of the neural marker genes was the result of the speci®c binding of the protein to the target DNA.
Discussion
XlPOU 2 is an activator of transcription
Our results indicate that XlPOU 2 activates neuronal differentiation by activating its target genes during mid-to late gastrulation. Injection of several doses of VP16-POU-GR (20, 50, 100, or 200 pg mRNA) resulted in the expansion of nrp-1 and the ectopic expression of b -tubulin. The injection of full length wild-type XlPOU 2-GR (40 or 200 pg mRNA) also displayed similar phenotype. Furthermore, expression of VP16-POU-GR or full length wild-type XlPOU 2-GR in animal caps led to the induction of the same pro®le of neural-speci®c genes. In contrast, the targeted expression of ENG-POU-GR (60±300 pg mRNA) resulted in an opposite phenoptype of VP16-POU-GR, speci®cally, the loss of neural tissue. Furthermore, overexpression of the dominant-inhibitory form of XlPOU 2 in animal caps repressed neuralization by chordin as assessed by the expression of two neural-speci®c markers, Zic-3 and nrp-1. These ®ndings provide strong evidence to demonstrate that XlPOU2's acts as an activator of transcription, and is essential for neural development in Xenopus. Recent studies in Xenopus suggest that both activators and repressors of transcription regulate the process of neural induction. For instance, repressors such as Zic-2 (Brewster et al., 1998) and XBF-2 (Mariani and Harland, 1998) as well as bimodal factors such as XBF-1 (Bourguignon et al., 1998) act to in¯uence the patterning of the neural plate. As a transcriptional activator, XlPOU 2 will most likely act in conjunction with a complex array of both transcriptional activators and repressors to de®ne neural fate and neuronal differentiation in the neural plate.
The class III POU domain gene, XlPOU 2, is required for the proper formation of the brain
Class III POU genes are essential for neuronal speci®ca-tion in the nervous system. For example, gene disruption studies show that Brn-2 is required for the speci®cation of neurons in the hypothalamus of the mouse (Nakai et al., 1995; Schonemann et al., 1995) , while tst-1/SCIP/oct-6 is required for Schwann cell differentiation (Bermingham et al., 1996; Jaegle et al., 1996) . In support of an early role of class III POU genes in neural development, it has been suggested that class III POU genes can regulate the expression of CNS stem cell gene expression in the mouse (Josephson et al., 1998) . Our loss-of-function experiments in Xenopus provide direct evidence that the class III POU gene, XlPOU 2, is required for neural-speci®c gene expression. In Xenopus, XlPOU 2 probably plays an unique role in neural fate determination since it is expressed during gastrulation in the presumptive neuroectoderm (Witta et al., 1995) , a developmental time period much earlier than at least two other class III POU genes, XlPOU 1 and XlPOU 3. In Xenopus, XlPOU 1 (Agarwal and Sato, 1991) and the Brn-2 homolog, XlPOU 3, (Baltzinger et al., 1996) , are not expressed until the late neural plateneurula stage, and therefore, are unlikely to be involved in regulating neural fate determination. Interestingly, mutations in POU3F4 (the human homolog of XlPOU 2) result in deafness due to a defect in development of the stapes, but there are no discernible defects in early nervous system development (de Kok et al., 1995) . Perhaps in humans, another class III POU domain protein may subserve the requirement for class III POU gene activity in neural determination. Alternatively, it is probable that this process is dependent upon a number of transcriptional regulators, some of which are redundant. Therefore, it is prudent to employ both gain-of-function as well as loss of function studies to unravel the function of genes that act in neural determination and neuronal differentiation.
Potential regulation of en-2 by XlPOU 2 in the MHB during neurulation
The ®nding that XlPOU 2 may play a role in determining the MHB is not surprising because XlPOU 2 is highly expressed in an overlapping domain with en-2 (Fig. 5A±  D) . However, since en-2 and XlPOU 2 are expressed during neurulation, the inhibition of en-2 expression by ENG-POU-GR in the MHB may occur independently from the blockade of neuralization by ENG-POU-GR that occurs during gastrulation. Interestingly, VP16-POU-GR did not induce en-2 expression in animal cap ectoderm (data not shown), suggesting that additional factors are required for the proper formation of the MHB in the embryo.
Evidence for the potential cross-regulation of XlPOU 2 and the pre-pattern genes during neural determination
The activation of the pre-pattern genes, Zic r1 and Zic 3 is dependent on the secretion of noggin or chordin from the organizer at the beginning of gastrulation. Planar signals or maternal factors present in the early to late blastula stage embryo may also regulate the expression of the pre-pattern genes (Kuo et al., 1998) . Because the pre-pattern genes are expressed at the beginning of gastrulation, they are likely candidates for inducing XlPOU 2 during mid-gastrulation. Therefore, we examined the pre-pattern genes, Zic 3 and Zic r1 for their ability to induce XlPOU 2. However, in an animal cap assay, XlPOU 2 was induced only weakly by the pre-pattern genes, Zic r1 and Zic 3, suggesting that there are other factors or perhaps combinations of factors that contribute signi®cantly to the induction of XlPOU 2 in the neuroectoderm during mid-gastrulation. Interestingly, XlPOU 2 is capable of inducing Zic r1 and Zic 3 in an animal cap assay. These data provide evidence for the potential cross-regulation that might occur between XlPOU 2 and the Zic genes during neural determination. Although XlPOU 2 cannot be responsible for the initial activation of the pre-pattern genes at the beginning of gastrulation, it is likely that XlPOU 2 may enhance prepattern gene expression later in gastrulation (Fig. 8) . Indeed, cross-regulatory features are not uncommon in other developing systems. For instance, a single transcriptional factor can interact with both upstream and downstream partners during myogenesis (Edmonson et al., 1992; Naidu et al., 1995) , during early tooth development (Bei and Mass, 1998) , and throughout T-cell development (for a review, see Clevers and Ferrier, 1998) . Perhaps, such mechanisms allow for a ®ner regulatory control within a developmental pathway.
What genes are downstream from XlPOU 2?
As illustrated in Fig. 8 , XlPOU 2 is upstream from Xngnr-1 (atonal-related), a neuronal determinant gene expressed in all primary neurons. Although XlPOU 2 induces X-ngnr-1 readily, X-ngnr-1 is not capable of inducing XlPOU 2 in an animal cap induction assay. XlPOU 2's activation of X-ngnr-1, then leads to the induction of btubulin.
In summary, we demonstrate that XlPOU 2 functions as a transcriptional activator during gastrulation, mediating neural determination, and show that its activity is essential for the proper formation of neural tissue. XlPOU 2 is induced by the pre-pattern genes Zic r1 and Zic 3, and it is epistatic to the neuronal determinant, X-ngnr-1.
Experimental procedures
Construction of hormone-inducible VP16-POU-GR, ENG-POU-GR, and XlPOU 2-GR
The predicted transactivation domain of XlPOU 2, based on mapping studies of Brain 4, the mammalian homolog of XlPOU 2 (Mathis et al., 1992) , was replaced by either the strong activation domain of VP16 or the strong repressor domain of engrailed (Jaynes and O'Farrell, 1991; Conlon et al., 1996; Kessler, 1997; Henry and Melton, 1998; Lemaire et al., 1998) . The POU DNA binding domain of XlPOU 2 was ampli®ed from the pSP64T-XlPOU 2 plasmid (Witta and Sato, 1997) H . Products were digested with XhoI and XbaI (underlined), and inserted in frame at the XhoI-XbaI sites in pCS2 VP16-N (including the VP16 activator domain) or pCS2 ENG-N (including the engrailed repressor domain), respectively. The ligand-binding domain of the human glucocorticoid Fig. 8 . Model of XlPOU 2's role in neural fate determination and neuronal differentiation. A cascade of transcriptional regulators in the early vertebrate neural developmental pathway is shown. Antagonism of BMP initiates the process of neural induction. Subsequently, the pre-pattern genes, Zic r1 and Zic 3 induce XlPOU 2, but only weakly. Moreover, XlPOU 2 positively regulates pre-pattern gene expression later in gastrulation. It is likely that an unknown factor(s) or combinations of pre-pattern genes are required to induce signi®cant amounts of XlPOU 2. XlPOU 2 is a neural fate determinant, acting during mid-to late gastrulation. It is upstream of X-ngnr-1, a neuronal determination gene, and can induce the expression of b -tubulin, a marker of terminal neuronal differentiation.
receptor (Hollenberg et al., 1985) was ampli®ed from the plasmid pSP64T-MyoD-GR (Hollenberg et al., 1993; Kolm and Sive, 1995) by PCR with the primers: 5 H -AGTCAGTCTCTAGAAACCTCT-GAAAATCCTGGTAAC-3 H and 5
H -AGTCAGTCTCTAGATCACTTTTGATGAAACA-GAAG-3
H . The resulting products were digested with XbaI (underlined) and inserted in frame at the XbaI site in the VP16-POU or ENG-POU plasmids and they were named VP16-POU-GR or ENG-POU-GR, respectively (Fig. 1B,D) .
In order to determine the speci®city of VP16-POU-GR and ENG-POU-GR, the third helix of POU homeodomain of XlPOU 2 was deleted using PCR with the primers:
H and 5
H -AGTCAGTCTCTAGACTCTAGTTG-CAGGCTGTCTGCCAAG-3
H . The resulting product (574± 954 bp) was ligated to the pCS2 VP16-N or pCS2 ENG-N using the same procedure as described above to generate VP16-POU-DEL-GR (Fig 1C) and ENG-POU-DEL-GR (Fig. 1E) constructs.
The full length XlPOU 2-GR (Fig. 1A) was created by amplifying the 5 H region of XlPOU 2 (1-573bp) by PCR with the primers: 5 H -AGTCAGTCATCGATATGGCCACGGCTGCCTC-TAAT-3 H and 5
H -AGTCAGTCACTCGAGT-GATGTTGGGGTCTCCTCGCT-3 H . The resulting product was then digested with ClaI and XhoI (underlined), and ligated to POU-GR. Finally, capped mRNA for microinjection were produced by linearizing the above plasmids with SacII and transcribing the corresponding mRNA using SP6 RNA polymerase as described previously (Witta et al., 1995) .
Microinjection and embryo manipulations
Xenopus laevis eggs were collected and fertilized as described previously (Witta et al., 1995; Witta and Sato, 1997) . Embryos were staged according to Nieuwkoop and Faber (1967) , and aligned on grids for microinjection at the 2±4 cell stage. For targeting the expression of constructs into a speci®c lineage, either a ventral animal blastomere or dorsal animal blastomere at the 8±16 cell stage was microinjected with the appropriate mRNA. Embryos were treated with 10 mM dexamethasone (dex) (Sigma Chemicals) in 0.1X MMR at stage 11 or 14 as described in Gammill and Sive (1997) , and collected at the neurulaearly tailbud stage. Two hundred pg of lacZ mRNA was co-injected as a lineage tracer (Detrick et al., 1990) . Furthermore, to test the speci®city of the targeting experiments, constructs without the GR domain (100 pg mRNA) were microinjected into a dorsal animal blastomere at the 16-cell stage, and the expression of gsc, an organizer-speci®c gene (Cho et al., 1991) was assessed at stage 10.5 by in situ hybridization. When either the repressor or activator constructs were micronjected into a dorsal animal blastomere, no changes in gsc expression were observed, suggesting that organizer function was not altered (S. Sato, unpublished observations). For animal cap experiments, embryos were microinjected with 50 or 200 pg of corresponding mRNA at the 2±4 cell stage and uncommitted ectoderm (animal caps) were dissected at stage 9. Animal caps were cultured until sibling control embryos reached stage 11, and they were then treated with 10 mM dex in 0.5 £ MMR until stage 13±14 or neurula stage. After the coinjection of embryos with the chordin and ENG-POU-GR mRNAs, embryos and caps were cultured in the presence of 10 mM dex in 0.3£ MMR until sibling control embryos reached stage 16±17.
In situ hybridization and lineage analysis
Whole-mount in situ hybridization was performed as described previously (Harland, 1991; Knecht et al., 1995) using digoxygenin or¯uorescein-labeled antisense probes for nrp-1 (Richter et al., 1990) , epidermal keratin (DG81) (Jonas et al., 1985) , en-2 (Hemmati-Brivanlou et al., 1991), XlPOU 2 (Witta et al., 1995) or b -tubulin (Good et al., 1989) . For single probe experiments, BM-purple (Boehringer Mannheim) was used as the alkaline phosphatase (AP) substrate. For double in situ hybridization experiments (Fig.  5C ), en-2/XlPOU 2 expression was visualized with the AP substrates, magenta-phosphate (Biosynth AG) and BCIP (Boehringer Mannheim), respectively. To visualize the lineage tracer, b-galactosidase (b -gal) staining was performed as described previously (Detrick et al., 1990; Witta and Sato, 1997 ) using X-gal (Life Technologies) as the substrate. Only correctly injected embryos (approximately 80% of the total injected embryos) were selected for the in situ hybridization analysis.
For sectioning, stained embryos were rehydrated in PBS and transferred gradually to 30% sucrose at 48C, and then embedded in OCT compound (Miles Inc.) at 2208C. Coronal sections (15±30 mm) were cut in cryostat, mounted on slides, dehydrated in ascending series of ethanol, and coverslipped with crystal/mount (Biomeda). They were then visualized using a Zeiss Axioskop, and images were captured using a Hamamatsu color chilled 3CCD camera system.
RNA isolation and RT-PCR
Preparation of total RNA and the RT-PCR were performed as described previously (Witta et al., 1995; Witta and Sato, 1997 H . All PCR conditions were semi-quantitative, and in the linear range of detection. All conditions for the PCR were optimized in terms of cycle number and temperature for each set of primers as well as samples. The following conditions were used for the PCR (annealing temperature, number of cycles): XlPOU 2 (62.58C, 27 cycles), Zic r1, Zic 3 (558C, 25 cycles), X-ngnr-1 (558C, 28 cycles), Xbra (558C, 23 cycles), muscle-speci®c actin (558C, 20 cycles), b -tubulin (558C, 23 cycles), nrp-1 (558C, 25 cycles), and Ef1a (558C, 20 cycles).
Northern blot analysis
Methylmercury hydroxide gel electrophoresis and northern blot analysis of Zic 3, nrp-1, M-actin, and L1 (Loreni et al., 1985) RNA expression were performed as described previously (Sargent et al., 1986) . RNA expression of Zic 3 and nrp-1 was compared in dex-treated and non-dex-treated animal caps, and differences were quanti®ed using a Macbeth TD932 densitometer in linear exposures of X-ray ®lm.
